Johnson & Johnson $JNJ Position Cut by Legacy Private Trust Co.

Legacy Private Trust Co. decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 39,740 shares of the company’s stock after selling 2,214 shares during the quarter. Legacy Private Trust Co.’s holdings in Johnson & Johnson were worth $8,224,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of JNJ. Abich Financial Wealth Management LLC acquired a new position in Johnson & Johnson during the 3rd quarter valued at about $26,000. Evolution Wealth Management Inc. acquired a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $27,000. Clayton Financial Group LLC bought a new stake in shares of Johnson & Johnson during the third quarter valued at approximately $28,000. Semmax Financial Advisors Inc. raised its holdings in shares of Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after buying an additional 72 shares during the last quarter. Finally, Turning Point Benefit Group Inc. acquired a new position in shares of Johnson & Johnson during the third quarter worth approximately $41,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on JNJ. Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a research report on Wednesday, January 28th. Bank of America reiterated a “neutral” rating on shares of Johnson & Johnson in a research report on Monday, March 2nd. Morgan Stanley set a $253.00 price target on Johnson & Johnson in a report on Wednesday, March 18th. Wall Street Zen cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Finally, Guggenheim upped their price objective on shares of Johnson & Johnson from $227.00 to $240.00 and gave the stock a “buy” rating in a report on Friday, January 23rd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $236.91.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 1,322 shares of the company’s stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $245.66, for a total value of $324,762.52. Following the completion of the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,251,310.02. This represents a 4.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the transaction, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 30,142 shares of company stock valued at $7,360,528 over the last three months. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Performance

JNJ opened at $235.64 on Tuesday. The business has a 50 day moving average price of $235.73 and a two-hundred day moving average price of $209.21. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. The company has a market capitalization of $567.57 billion, a price-to-earnings ratio of 21.33, a price-to-earnings-growth ratio of 2.32 and a beta of 0.34. Johnson & Johnson has a 1-year low of $141.50 and a 1-year high of $251.71.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The company had revenue of $24.28 billion for the quarter. Research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th were given a $1.30 dividend. The ex-dividend date was Tuesday, February 24th. This represents a $5.20 annualized dividend and a yield of 2.2%. Johnson & Johnson’s payout ratio is 47.06%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.